However many shareholders have stakes in both Celgene and BMS, meaning that they stand to face less risk from the deal. Investors will get to vote on the acquisition in a special meeting scheduled ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...

The Big Pharma companies made a last-ditch effort asking a U.S. appeals court to reconsider their lawsuits against the ...

We've identified the following companies as similar to null because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Quirk joins Biogen from BMS, where he most recently served as SVP of worldwide medical affairs for immunology and neuroscience. Prior to that, he served as SVP of U.S. medical affairs and VP of U.S.

11 University of Pennsylvania, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Philadelphia, PA, United States of America 12 University of Pennsylvania, Division ...